6:21 PM
 | 
Aug 11, 2014
 |  BC Extra  |  Company News

Cologuard gets green light from FDA, CMS

FDA approved Cologuard from Exact Sciences Corp. (NASDAQ:EXAS) as a non-invasive DNA screening test for colorectal cancer. Separately, CMS issued a proposed National Coverage Determination (NCD) for Cologuard, the first product reviewed through a pilot parallel FDA/CMS...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >